BR0108609A - Anticorpo com especificidade pelo câncer de cólon - Google Patents
Anticorpo com especificidade pelo câncer de cólonInfo
- Publication number
- BR0108609A BR0108609A BR0108609-0A BR0108609A BR0108609A BR 0108609 A BR0108609 A BR 0108609A BR 0108609 A BR0108609 A BR 0108609A BR 0108609 A BR0108609 A BR 0108609A
- Authority
- BR
- Brazil
- Prior art keywords
- target
- colon cancer
- specific antibody
- cancer specific
- binds
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"ANTICORPO COM ESPECIFICIDADE PELO CâNCER DE CóLON". Uma estrutura de ligação a qual se liga em e/ou à superfície de células de tumor; uma estrutura alvo visualizada e/ou expressa em e/ou sobre a superfície de células de tumor; uma estrutura de ligação que reconhece e bloqueia a referida estrutura alvo; uma substância que se liga ou bloqueia a expressão da referida estrutura alvo; composições farmacêuticas compreendendo a referida estrutura de ligação, estruturas alvo ou substância como princípios ativos; composições de vacina compreendendo as referidas estruturas alvo como princípios ativos; um método para seleção por fago; e métodos de diagnose e prognose in vitro e in vivo e de tratamento de doenças malignas humanas compreendendo o uso das matérias em questão acima, são descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000597A SE0000597D0 (sv) | 2000-02-24 | 2000-02-24 | Novel antibody |
PCT/SE2001/000395 WO2001062286A1 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0108609A true BR0108609A (pt) | 2002-11-19 |
Family
ID=20278567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108609-0A BR0108609A (pt) | 2000-02-24 | 2001-02-23 | Anticorpo com especificidade pelo câncer de cólon |
Country Status (22)
Country | Link |
---|---|
US (1) | US7425623B2 (pt) |
EP (1) | EP1257291A1 (pt) |
JP (1) | JP2003523213A (pt) |
KR (1) | KR20020079888A (pt) |
CN (1) | CN1406136A (pt) |
AU (1) | AU775876B2 (pt) |
BR (1) | BR0108609A (pt) |
CA (1) | CA2400661A1 (pt) |
EE (1) | EE200200473A (pt) |
HK (1) | HK1052648A1 (pt) |
HU (1) | HUP0300007A3 (pt) |
IL (1) | IL151325A0 (pt) |
MX (1) | MXPA02008315A (pt) |
NO (1) | NO20023670L (pt) |
NZ (1) | NZ520523A (pt) |
PL (1) | PL356386A1 (pt) |
RU (1) | RU2268068C2 (pt) |
SE (1) | SE0000597D0 (pt) |
SK (1) | SK11982002A3 (pt) |
WO (1) | WO2001062286A1 (pt) |
YU (1) | YU63702A (pt) |
ZA (1) | ZA200206039B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008450A1 (fr) * | 2001-06-12 | 2003-01-30 | Kyogo Itoh | Antigenes tumoraux |
US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
CN1303105C (zh) * | 2003-12-08 | 2007-03-07 | 陈志南 | 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用 |
TWI429658B (zh) * | 2006-06-07 | 2014-03-11 | Bioalliance Cv | 辨認癌症細胞上表現的cd43與cea之含碳水化合物抗原決定區的抗體及其使用方法 |
EP2048241B1 (en) * | 2007-10-08 | 2012-07-25 | Sividon Diagnostics GmbH | Method employing GAPDH as molecular markers for cancer prognosis |
JP5568478B2 (ja) * | 2007-12-18 | 2014-08-06 | バイオアライアンス セー.フェー. | 癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法 |
ES2432537T3 (es) * | 2008-09-01 | 2013-12-04 | National University Corporation Nagoya University | Pronóstico de cánceres de colon |
FR2945952B1 (fr) * | 2009-05-27 | 2013-10-04 | Univ Claude Bernard Lyon | Anticorps anti-ck8 pour utilisation comme medicament. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798257A (en) * | 1990-07-09 | 1998-08-25 | Research Corporation Technologies, Inc. | Nucleic acid encoding human MTS-1 protein |
US5994088A (en) * | 1991-03-08 | 1999-11-30 | Board Of Trustees Of The University Of Illinois | Methods and reagents for preparing and using immunological agents specific for P-glycoprotein |
JP3782100B2 (ja) * | 1992-08-07 | 2006-06-07 | エピミューン,インコーポレイティド | Hla結合性ペプチド及びその用途 |
US5972643A (en) * | 1994-06-17 | 1999-10-26 | Fred Hutchinson Cancer Research Center | Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor |
WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
US20020193571A1 (en) * | 1996-01-08 | 2002-12-19 | Paul J. Carter | Wsx receptor agonist antibodies |
EP0879183A1 (fr) | 1996-07-18 | 1998-11-25 | Montania | Bouchon avec recipient auxiliaire et procede de realisation |
EP0934526B1 (en) * | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
SE9700291D0 (sv) * | 1997-01-31 | 1997-01-31 | Pharmacia & Upjohn Ab | Selection method and prodcts resulting therefrom |
ES2246069T3 (es) * | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
JP2001513995A (ja) * | 1997-08-29 | 2001-09-11 | セレクティブ ジェネティックス, インコーポレイテッド | 遺伝子送達のためのインターナリゼーションリガンドを選択するためのファージディスプレイを使用する方法 |
DE19739525A1 (de) * | 1997-09-09 | 1999-09-30 | Heinrich Abbrederis | Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen |
EP0934953A2 (en) * | 1997-12-03 | 1999-08-11 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
IL144559A0 (en) * | 1999-03-01 | 2002-05-23 | Genentech Inc | Antibodies for cancer therapy and diagnosis |
-
2000
- 2000-02-24 SE SE0000597A patent/SE0000597D0/xx unknown
-
2001
- 2001-02-23 RU RU2002125386/15A patent/RU2268068C2/ru not_active IP Right Cessation
- 2001-02-23 CN CN01805577A patent/CN1406136A/zh active Pending
- 2001-02-23 JP JP2001561350A patent/JP2003523213A/ja not_active Withdrawn
- 2001-02-23 AU AU36294/01A patent/AU775876B2/en not_active Ceased
- 2001-02-23 HU HU0300007A patent/HUP0300007A3/hu unknown
- 2001-02-23 PL PL01356386A patent/PL356386A1/xx not_active Application Discontinuation
- 2001-02-23 IL IL15132501A patent/IL151325A0/xx unknown
- 2001-02-23 YU YU63702A patent/YU63702A/sh unknown
- 2001-02-23 KR KR1020027010963A patent/KR20020079888A/ko not_active Application Discontinuation
- 2001-02-23 EE EEP200200473A patent/EE200200473A/xx unknown
- 2001-02-23 WO PCT/SE2001/000395 patent/WO2001062286A1/en active IP Right Grant
- 2001-02-23 US US10/182,132 patent/US7425623B2/en not_active Expired - Fee Related
- 2001-02-23 MX MXPA02008315A patent/MXPA02008315A/es unknown
- 2001-02-23 CA CA002400661A patent/CA2400661A1/en not_active Abandoned
- 2001-02-23 BR BR0108609-0A patent/BR0108609A/pt not_active IP Right Cessation
- 2001-02-23 EP EP01908551A patent/EP1257291A1/en not_active Withdrawn
- 2001-02-23 NZ NZ520523A patent/NZ520523A/en unknown
- 2001-02-23 SK SK1198-2002A patent/SK11982002A3/sk not_active Application Discontinuation
-
2002
- 2002-07-29 ZA ZA200206039A patent/ZA200206039B/en unknown
- 2002-08-02 NO NO20023670A patent/NO20023670L/no not_active Application Discontinuation
-
2003
- 2003-07-09 HK HK03104939.3A patent/HK1052648A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SK11982002A3 (sk) | 2003-03-04 |
MXPA02008315A (es) | 2002-12-09 |
HK1052648A1 (zh) | 2003-09-26 |
AU3629401A (en) | 2001-09-03 |
EP1257291A1 (en) | 2002-11-20 |
EE200200473A (et) | 2004-02-16 |
YU63702A (sh) | 2006-01-16 |
US7425623B2 (en) | 2008-09-16 |
JP2003523213A (ja) | 2003-08-05 |
NO20023670L (no) | 2002-08-23 |
RU2268068C2 (ru) | 2006-01-20 |
CN1406136A (zh) | 2003-03-26 |
PL356386A1 (en) | 2004-06-28 |
US20030176661A1 (en) | 2003-09-18 |
AU775876B2 (en) | 2004-08-19 |
KR20020079888A (ko) | 2002-10-19 |
ZA200206039B (en) | 2003-07-29 |
WO2001062286A1 (en) | 2001-08-30 |
CA2400661A1 (en) | 2001-08-30 |
NO20023670D0 (no) | 2002-08-02 |
NZ520523A (en) | 2004-08-27 |
RU2002125386A (ru) | 2004-03-20 |
IL151325A0 (en) | 2003-04-10 |
HUP0300007A2 (en) | 2003-05-28 |
HUP0300007A3 (en) | 2005-11-28 |
SE0000597D0 (sv) | 2000-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510274B8 (pt) | uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico | |
BR0209177A (pt) | Anticorpo especìfico a tumor recombinante e uso do mesmo | |
AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
BR0111220A (pt) | Conjugados de fármacos de etilenocisteìna (ec) | |
BR0213224A (pt) | agente de ligação especìfico, hibridoma, conjugado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de fabricar um agente de ligação especìfico, de fabricar um anticorpo, de unibir a angiogênese indesejada em um mamìfero e de tratar cáncer em um mamìfero, composição farmacêutica, métodos de modular ou inibir a atividade da angiopoietina-2, de modular pelo menos um dentre a permeabilidade vascular ou o vazamento de plasma em um mamìfero, de tratar doença e de detectar o nìvel de angiopoietina-2 em uma amostra biológica, e, anticorpo | |
BRPI0210886B8 (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal | |
BR0012069A (pt) | Composições e métodos para a terapia e diagnóstico de câncer pulmonar | |
TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
BR0008161A (pt) | Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral | |
BR9912007A (pt) | Composições e métodos para terapia e diagnóstico de câncer de próstata | |
ATE229073T1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
WO2004031411A3 (en) | Genes and polypeptides relating to human pancreatic cancers | |
AR006250A1 (es) | Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico | |
BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
BRPI0412885A (pt) | polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf) | |
AR031250A1 (es) | Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon | |
PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
BRPI0515175A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
ATE335515T1 (de) | Morpholinobildgebung und therapie | |
BR0108609A (pt) | Anticorpo com especificidade pelo câncer de cólon | |
ECSP034617A (es) | Kit de repinotan | |
RS20100249A (en) | CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE | |
BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009 |